Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01171664 · ClinicalTrials.gov registry record · Phase 2
Clinical Trial of STAHIST in Seasonal Allergic Rhinitis (SAR) Subjects
A Phase 2 study of Seasonal Allergic Rhinitis, sponsored by Magna Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
- 2
- Study locations
NCT01171664: Completed Phase 2 study of Seasonal Allergic Rhinitis, sponsored by Magna Pharmaceuticals.
NCT01171664 is a Phase 2 study of Seasonal Allergic Rhinitis that has completed, run by Magna Pharmaceuticals. The registered enrollment target is 100 participants, below the 662-participant average among 16 other Seasonal Allergic Rhinitis trials with a reported enrollment target (85% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01171664, a Phase 2 study of Seasonal Allergic Rhinitis, has completed, sponsored by Magna Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
- 2
- Study locations
Study Summary
To report and compare total symptom scores, nasal symptom scores, post-nasal drip symptom scores, and adverse reactions in and between SAR subjects on active drug and SAR subjects on placebo.
Primary Outcome
TSS includes the sum of nasal congestion, rhinorrhea, nasal itching, sneezing, and post-nasal drip
Conditions Studied
Interventions
- DRUG Placebo
- DRUG STAHIST
Study Locations (2)
Indiana
- The South Bend Clinic - South Bend
Kentucky
- Family Allergy & Asthma Research Institute - Louisville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2010-09 |
| Est. Completion | 2011-01 |
| Phase | Phase 2 |
What the finished NCT01171664 record still lists
NCT01171664 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 662-participant average among 16 other Seasonal Allergic Rhinitis trials with a reported enrollment target (85% lower).
The record links to 1 condition, with Seasonal Allergic Rhinitis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01171664 reports a single indexed study location in Indiana, Kentucky.
Frequently Asked Questions
What is clinical trial NCT01171664 about?
NCT01171664 is a clinical study titled "Clinical Trial of STAHIST in Seasonal Allergic Rhinitis (SAR) Subjects". To report and compare total symptom scores, nasal symptom scores, post-nasal drip symptom scores, and adverse reactions in and between SAR subjects on active drug and SAR subjects on placebo.
What is the current status of trial NCT01171664?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2010-09. Estimated completion is 2011-01.
What conditions does trial NCT01171664 study?
This clinical trial studies the following conditions: Seasonal Allergic Rhinitis.
What interventions are being tested in trial NCT01171664?
The interventions under investigation include: Placebo (DRUG), STAHIST (DRUG).
Who is sponsoring clinical trial NCT01171664?
This trial is sponsored by Magna Pharmaceuticals, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01171664 being conducted?
This trial has 2 study locations across Indiana, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Seasonal Allergic Rhinitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01171664's enrollment target sits among peer trials
100 15th of 16 higher than 2 of 16 other Seasonal Allergic Rhinitis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Seasonal Allergic Rhinitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Dose Selection Study of Efficacy and Safety of Different Doses of Grass MATA MPL and Grass MATA Using mEECs™
COMPLETED · Phase 2
-
Study of ACT-129968 in Adult Patients With Seasonal Allergic Rhinitis
COMPLETED · Phase 2
-
Safety and Efficacy of Bepotastine Besilate Nasal Spray in the Treatment of Seasonal Allergic Rhinitis
COMPLETED · Phase 2
-
Efficacy and Safety of Fixed Dose Combination GSP 301 Nasal Spray (NS) in the Treatment of Seasonal Allergic Rhinitis (SAR)
COMPLETED · Phase 3
-
Safety and Efficacy of Ciclesonide in Pediatric Patients (6 to 11 Years of Age) With Seasonal Allergic Rhinitis (BY9010/M1-417)
COMPLETED · Phase 3
-
Comparison of Olopatadine 0.6% and Fluticasone Proprionate 50mcg Nasal Sprays in a Two Week Seasonal Allergic Rhinitis Trial
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia